SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2026)
SAB Biotherapeutics (SABS) posted Profit After Tax of -$18.9 million for Q1 2026, down 11.91% on a QoQ basis from -$16.9 million in Q4 2025, and down 263.09% year-over-year from $11.6 million in Q1 2025.
SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$18.9 million for Q1 2026.
- Quarterly Profit After Tax fell 263.09% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$398429.0 (up 98.84% YoY) and the FY2025 annual result came in at $13.3 million, up 138.92% from the prior year.
- Profit After Tax was -$18.9 million for Q1 2026 at SAB Biotherapeutics, down from -$16.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at $45.4 million in Q3 2025 and bottomed at -$22.9 million in Q4 2023.
- A 5-year average of -$5.9 million and a median of -$7.3 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax plunged 845.93% — and 2025, when it surged 539.11%.
- SAB Biotherapeutics' Profit After Tax stood at -$7.9 million in 2022, then slumped by 190.26% to -$22.9 million in 2023, then surged by 50.15% to -$11.4 million in 2024, then slumped by 47.97% to -$16.9 million in 2025, then decreased by 11.91% to -$18.9 million in 2026.
- Business Quant data shows SABS's Profit After Tax at -$18.9 million in Q1 2026, -$16.9 million in Q4 2025, and $45.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -16.86 Mn |
| Sep 30, 2025 | 45.45 Mn |
| Jun 30, 2025 | -10.11 Mn |
| Mar 31, 2025 | -5.20 Mn |
| Dec 31, 2024 | -11.39 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |